A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
When used in this report, unless otherwise indicated, “Nurix,” “Company,” “we,” “us” and “our” refers to Nurix Therapeutics, Inc. and its wholly owned subsidiaries. We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully artificial intelligence (AI)-integrated discovery engine capable of tackling any protein class, and coupled with leading ligase expertise, Nurix has built a significant advantage in translating the science of protein degradation into clinical advancements with the aim of establishing degrader-based treatments at the forefront of patient care.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | 77M | - | - |
| Net Income | -264M | -264M | -194M | -144M | -180M | -117M |
| EPS | $-3.05 | $-3.05 | $-2.88 | $-2.65 | $-3.71 | $-2.73 |
| Free Cash Flow | -263M | -263M | -182M | -90M | -172M | -90M |
| ROIC | -41.9% | -49.1% | -36.7% | -71.8% | -59.4% | -34.2% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.28 | 0.27 | 0.77 | 0.37 | 0.39 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -286M | -286M | -213M | -155M | -184M | -118M |
| Operating Margin | 0.0% | - | - | -201.4% | - | - |
| ROE | -49.1% | -49.6% | -36.7% | -71.8% | -59.4% | -34.2% |
| Shares Outstanding | 87M | 87M | 67M | 54M | 49M | 43M |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 31M | N/A | N/A | N/A | 77M | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -22M | -65M | -118M | -184M | -155M | -213M | -286M | -286M |
| Op. Margin | -71.5% | N/A | N/A | N/A | -201.4% | N/A | N/A | 0.0% |
| Net Income | -22M | -43M | -117M | -180M | -144M | -194M | -264M | -264M |
| Net Margin | -69.7% | N/A | N/A | N/A | -187.0% | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||||
| ROIC | -39.9% | -14.9% | -34.2% | -59.4% | -71.8% | -36.7% | -49.1% | -41.9% |
| ROE | N/A | -14.9% | -34.2% | -59.4% | -71.8% | -36.7% | -49.6% | -49.1% |
| ROA | -49.3% | -10.9% | -24.6% | -43.3% | -40.5% | -28.9% | -39.0% | -38.4% |
| Cash Flow | ||||||||
| Op. Cash Flow | 601K | -80K | -84M | -160M | -81M | -173M | -249M | -249M |
| Free Cash Flow | -1.1M | -4.6M | -90M | -172M | -90M | -182M | -263M | -263M |
| Owner Earnings | -2.3M | -6.6M | -103M | -193M | -123M | -216M | -296M | -296M |
| CapEx | 1.7M | 4.6M | 5.7M | 12M | 8.4M | 9.3M | 14M | 14M |
| Maint. CapEx | 2.4M | 2.2M | 2.8M | 5.3M | 7.5M | 9.3M | 8.7M | 8.7M |
| Growth CapEx | 0 | 2.4M | 2.9M | 6.9M | 868K | 0 | 5.3M | 5.3M |
| D&A | 2.4M | 2.2M | 2.8M | 5.3M | 7.5M | 9.3M | 8.7M | 8.7M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 510K | 4.3M | 16M | 28M | 34M | 34M | 38M | 38M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||
| Net Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0 |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | -1.76 | 0.37 | 0.39 | 0.37 | 0.77 | 0.27 | 0.28 | 0.00 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | -58M | 290M | 342M | 304M | 200M | 527M | 539M | 539M |
| Total Assets | 44M | 396M | 477M | 417M | 356M | 669M | 688M | 688M |
| Total Liabilities | 102M | 106M | 134M | 113M | 155M | 142M | 149M | 149M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -60M | -104M | -221M | -401M | -545M | -739M | -1.0B | -1.0B |
| Working Capital | 23M | 254M | 245M | 248M | 209M | 524M | 520M | 520M |
| Current Assets | 39M | 298M | 311M | 318M | 296M | 619M | 607M | 607M |
| Current Liabilities | 16M | 45M | 66M | 71M | 87M | 96M | 86M | 86M |
| Per Share Data | ||||||||
| EPS | -6.59 | -2.76 | -2.73 | -3.71 | -2.65 | -2.88 | -3.05 | -3.05 |
| Owner EPS | -0.06 | -0.42 | -2.40 | -3.98 | -2.26 | -3.21 | -3.42 | -3.42 |
| Book Value | -1.48 | 18.53 | 7.97 | 6.25 | 3.69 | 7.84 | 6.21 | 6.21 |
| Cash Flow/Share | 0.02 | -0.01 | -1.97 | -3.29 | -1.50 | -2.57 | -2.88 | -2.95 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 38.9M | 15.7M | 42.9M | 48.6M | 54.3M | 67.2M | 86.7M | 86.7M |
| Valuation | ||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -5.2 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 2.1 | 3.8 | 1.8 | 1.6 | 2.7 | 2.8 | 2.6 |
| Price/Sales | N/A | N/A | N/A | N/A | 6.6 | N/A | N/A | N/A |
| FCF Yield | N/A | -0.8% | -7.0% | -31.2% | -28.5% | -12.7% | -17.2% | -19.1% |
| Market Cap | N/A | 615M | 1.3B | 552M | 315M | 1.4B | 1.5B | 1.4B |
| Avg. Price | N/A | 26.66 | 33.23 | 15.87 | 9.42 | 17.04 | 13.18 | 15.91 |
| Year-End Price | N/A | 39.24 | 30.06 | 11.35 | 5.80 | 21.23 | 17.68 | 15.91 |
Nurix Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Nurix Therapeutics, Inc. (NRIX) has a 5-year average return on invested capital (ROIC) of -50.2%. This is below average and may indicate limited pricing power.
Nurix Therapeutics, Inc. (NRIX) has a market capitalization of $1.4B. It is classified as a small-cap stock.
Nurix Therapeutics, Inc. (NRIX) does not currently pay a regular dividend.
Nurix Therapeutics, Inc. (NRIX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Nurix Therapeutics, Inc. (NRIX) generated $-263 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Nurix Therapeutics, Inc. (NRIX) has a debt-to-equity ratio of 0.28. This indicates a conservatively financed balance sheet.
Nurix Therapeutics, Inc. (NRIX) reported earnings per share (EPS) of $-3.05 in its most recent fiscal year.
Nurix Therapeutics, Inc. (NRIX) has a return on equity (ROE) of -49.6%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 7 years of financial data for Nurix Therapeutics, Inc. (NRIX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Nurix Therapeutics, Inc. (NRIX) has a book value per share of $6.21, based on its most recent annual SEC filing.